Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Reduced by Weaver Capital Management LLC

Weaver Capital Management LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,381 shares of the biopharmaceutical company’s stock after selling 526 shares during the period. Weaver Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $984,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. KBC Group NV lifted its stake in Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after acquiring an additional 102,198 shares during the last quarter. Icon Wealth Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares during the last quarter. Finally, State Street Corp lifted its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $697.05 on Wednesday. The firm’s 50 day simple moving average is $719.16 and its 200 day simple moving average is $918.90. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $11.86 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Finally, Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $982.43.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.